Literature DB >> 12941678

Provision of pneumococcal prophylaxis for publicly insured children with sickle cell disease.

Colin M Sox1, William O Cooper, Thomas D Koepsell, David L DiGiuseppe, Dimitri A Christakis.   

Abstract

CONTEXT: It is recommended that children younger than 5 years with sickle cell disease (SCD) take daily prophylactic antibiotics to prevent pneumococcal infections; however, how much prophylactic medication they actually are dispensed is unclear.
OBJECTIVES: To measure the amount of prophylactic antibiotics dispensed to young children with SCD and to investigate factors associated with increased delivery of medication. DESIGN, SETTING, AND PATIENTS: Retrospective longitudinal study conducted January 1995 through December 1999 using Tennessee and Washington State Medicaid administrative claims and encounter data. Children (N = 261) who had 1 inpatient or 2 outpatient claims or encounters listing an International Classification of Diseases, Ninth Revision, Clinical Modification code for SCD, were younger than 4 years at study entry (mean age, 1.4 years), and were continuously enrolled in Medicaid for a 1-year period. MAIN OUTCOME MEASURE: Number of days during a 365-day period covered by prescription fills for a penicillin or macrolide antibiotic, or for trimethoprim-sulfamethoxazole.
RESULTS: In a 365-day period, patients were dispensed a mean of 148.4 (SD, 121.3; median, 114; interquartile range [IQR], 39-247) days of prophylactic medication. The total amount of medication dispensed varied widely: 10.3% of patients received none and 21.5% received more than 270 days of medication. In a 365-day period, a mean of 12.7 (SD, 10.5; range, 0-40) prophylactic prescriptions were filled per patient. The median prescription duration was 10 days. In a multivariate linear regression model adjusting for state, sex, age at study entry, inclusion year, residence in urban community, outpatient inclusion encounter, required prescription co-payment, and number of outpatient visits for nonpreventive care, each preventive visit was associated with 12.0 (95% confidence interval [CI], 2.3-21.7) additional days of prophylactic antibiotics, and each emergency department visit was associated with 10.0 (95% CI, 1.2-18.8) additional days.
CONCLUSIONS: Publicly insured children with SCD may receive inadequate antibiotic prophylaxis against pneumococcal infections, placing them at increased risk of morbidity and mortality; however, increased numbers of outpatient visits for preventive care are associated with improved provision of prophylactic antibiotics.

Entities:  

Mesh:

Year:  2003        PMID: 12941678     DOI: 10.1001/jama.290.8.1057

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  18 in total

1.  Sickle-cell disease in California: a population-based description of emergency department utilization.

Authors:  Julie A Wolfson; Sheree M Schrager; Thomas D Coates; Michele D Kipke
Journal:  Pediatr Blood Cancer       Date:  2010-11-24       Impact factor: 3.167

2.  Antibiotic Prophylaxis for Children With Sickle Cell Anemia.

Authors:  Sarah L Reeves; Alison C Tribble; Brian Madden; Gary L Freed; Kevin J Dombkowski
Journal:  Pediatrics       Date:  2018-02-05       Impact factor: 7.124

3.  Hydroxyurea Initiation Among Children With Sickle Cell Anemia.

Authors:  Sarah L Reeves; Hannah K Jary; Jennifer P Gondhi; Jean L Raphael; Lynda D Lisabeth; Kevin J Dombkowski
Journal:  Clin Pediatr (Phila)       Date:  2019-05-21       Impact factor: 1.168

4.  Association between clinical outcomes and metformin use in adults with sickle cell disease and diabetes mellitus.

Authors:  Sherif M Badawy; Amanda B Payne
Journal:  Blood Adv       Date:  2019-11-12

Review 5.  Medication adherence among pediatric patients with sickle cell disease: a systematic review.

Authors:  Kathleen E Walsh; Sarah L Cutrona; Patricia L Kavanagh; Lori E Crosby; Chris Malone; Katie Lobner; David G Bundy
Journal:  Pediatrics       Date:  2014-11-17       Impact factor: 7.124

Review 6.  Rigorous and practical quality indicators in sickle cell disease care.

Authors:  Suzette O Oyeku; Elissa Z Faro
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

7.  Sickle cell disease in California: sociodemographic predictors of emergency department utilization.

Authors:  Julie A Wolfson; Sheree M Schrager; Rachna Khanna; Thomas D Coates; Michele D Kipke
Journal:  Pediatr Blood Cancer       Date:  2011-02-25       Impact factor: 3.167

Review 8.  Systematic and Meta-Analytic Review: Medication Adherence Among Pediatric Patients With Sickle Cell Disease.

Authors:  Kristin Loiselle; Jennifer L Lee; Lauren Szulczewski; Sarah Drake; Lori E Crosby; Ahna L H Pai
Journal:  J Pediatr Psychol       Date:  2015-09-18

9.  Preventive Care Delivery to Young Children With Sickle Cell Disease.

Authors:  David G Bundy; John Muschelli; Gwendolyn D Clemens; John J Strouse; Richard E Thompson; James F Casella; Marlene R Miller
Journal:  J Pediatr Hematol Oncol       Date:  2016-05       Impact factor: 1.289

10.  Discontinuation of thyroid hormone treatment among children in the United States with congenital hypothyroidism: findings from health insurance claims data.

Authors:  Alex R Kemper; Lijing Ouyang; Scott D Grosse
Journal:  BMC Pediatr       Date:  2010-02-15       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.